ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2025
Improved Pharmacogenomic Testing Process for Veterans in Outpatient Settings by Clinical Pharmacist Practitioners.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pharmacogenomic Testing for Veterans (PHASER) is a US Department of Veterans Affairs (VA) program that offers a 16-gene laboratory test panel to patients. Pharmacogenomic testing results may improve patient care by providing patient-specific information on how effective a medication may be or identifying increased risks for adverse drug effects. A VA Central Ohio Healthcare System Pharmacy department initiative sought to increase outpatient PHASER ordering by clinical pharmacist practitioners (CPPs). Observations: CPPs were surveyed to address the current process and perceived barriers. Barriers identified by CPPs included a lack of clinician education materials, standardized screening process, comfort with PHASER ordering and education, support for the initiative, time constraints preventing patient education and ordering, higher priority clinical needs, forgetting to order, and increased workload and burnout. A gap analysis was used to create a new workflow with the goal of increasing PHASER orders by 50% after 3 months. The new workflow included prefilled templates, education, and visual reminders. PHASER orders increased from 87 preimplementation to 196 postimplementation, a 125% increase. Conclusions: This quality improvement initiative resulted in an increase in PHASER orders and a clearly defined process. Perceived barriers were identified, and process changes attempted to address them in a sustainable way.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.